Nanoparticles extend glioblastoma survival in phase one trial

Published Date: 02 Apr 2025

Despite decades of research to develop effective treatments, the median survival for glioblastoma—the most common malignant primary brain tumor in adults—is just 15–18 months after diagnosis. One reason for this grim ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

AI catches one-third of interval breast cancers missed at screening

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot